Clinical Trials Directory

Trials / Completed

CompletedNCT00452985

Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian Cancer

Randomised Study With Docetaxel, Cisplatin and Cyclophosphamide vs Docetaxel and Carboplatin as First Line Chemotherapy With Advanced or Metastatic Ovarian Cancer

Status
Completed
Phase
Study type
Observational
Enrollment
30 (actual)
Sponsor
Sanofi · Industry
Sex
Female
Age
15 Years – 75 Years
Healthy volunteers
Not accepted

Summary

Primary objective: To assess response rate. To record the clinical improvement in relation to stage and histopathological grading. Secondary objective: To determine progression free survival. To find out overall survival. To evaluate the safety of the study regimen.

Conditions

Interventions

TypeNameDescription
DRUGDocetaxel60-75 mg/m²
DRUGCarboplatinAUC 5

Timeline

Start date
2002-02-01
Primary completion
2010-11-01
Completion
2010-11-01
First posted
2007-03-28
Last updated
2012-08-14

Locations

1 site across 1 country: Bangladesh

Source: ClinicalTrials.gov record NCT00452985. Inclusion in this directory is not an endorsement.

Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian Cancer (NCT00452985) · Clinical Trials Directory